Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM61713 in NSCLC Patients With EGFR Mutation
NCT01588145Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2012
- Primary completion
- Aug 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of olmutinib in non-small cell lung cancer (NSCLC), sponsored by Hanmi Pharmaceutical. Started Mar 2012; status: completed.
02
Drugs
olmutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01588145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588145.